男生普通话版 下载mp3 女声普通话版 下载mp3 粤语版 下载mp3 西南方言版 下载mp3 东北话版 下载mp3 上海话版 下载mp3 今日优选 特朗普放松汽车关税政策，或考虑将AI芯片作为谈判新筹码 美国务卿再度暗示退出俄乌和谈，普京坚持要求控制乌克兰的4个地区 我国将开展市场准入壁垒清理整治行动 事关"中概股回流"，港交所与香港证监会已出动 市场盘点 周二，在美国贸易协议希望的支撑下，美元指数震荡走高，重回99关口上方，最终收涨0.28%，报99.21。美债收益率在美国经济数据表现不佳后急挫，基准 的10年期美债收益率收报4.181%；对货币政策更敏感的两年期美债收益率收报3.656%。 随着避险情绪有所降温，现货黄金回调，盘中一度失守3000美元大关，最终收跌0.81%，报3317.25美元/盎司。现货白银先涨后跌，美盘回吐日内全部涨 幅，最终收跌0.69%，报32.93美元/盎司。 由于美国经济数据显现出的压力迹象打击了需求前景，国际原油大跌。WTI原油跌跌不休，接连下破61、60两道关口，最终收跌2.84%，报59.93美元/桶， 创近三周新低；布伦特原油收跌2.48%，报63美元/桶。 美股三 ...

智通财经4月29日电，截至发稿，药明康德(02359.HK)涨4.90%、凯莱英(03759.HK)涨2.71%、昭衍新药 (06127.HK)涨1.87%。 部分港股医药外包概念股走强 药明康德涨近5% ...

Core Insights - The company reported a revenue of 1.541 billion yuan for Q1 2025, representing a year-on-year growth of 10.10% [1][2] - The net profit attributable to shareholders reached 327 million yuan, with a year-on-year increase of 15.83% [1][3] - The growth in net profit outpaced revenue growth by 5.73 percentage points, indicating improved efficiency [4] Revenue Performance - The revenue from the small molecule business remained stable compared to the same period last year, while the emerging business saw a significant growth of over 80% year-on-year [2] - The company is focusing on expanding its CDMO services in the small molecule sector, with an expectation of 12 projects in the validation batch stage for 2025 [5] Profitability Analysis - The net profit growth of 15.83% is attributed to the rapid development of emerging businesses and ongoing cost reduction and efficiency improvement efforts [4][5] - The company is optimistic about the continuous improvement of its performance in 2025, supported by a robust order reserve in the small molecule business and successful project validations in the peptide sector [5] Investment Outlook - The projected net profits for 2025 to 2027 are 1.133 billion yuan, 1.321 billion yuan, and 1.521 billion yuan, with year-on-year growth rates of 19.4%, 16.6%, and 15.1% respectively [6] - The expected EPS for 2025 is 3.14 yuan per share, with a target price of 94.20 yuan per share based on a PE ratio of 30 times, indicating a "Buy-A" investment rating [6]

华夏时报（www.chinatimes.net.cn）记者 张斯文 于娜 北京报道 百亿"赌局"崩盘！泰格医药净利润腰斩。 泰格医药（300347.SZ）2024年财报显示，公司营收与净利润双双大幅下滑，全年营收同比下降10.58%至66.03亿 元，归母净利润骤降79.99%。这一表现主要受国内创新药研发需求萎缩、订单价格竞争加剧，以及非经常性损益 项目的拖累。其中，金融资产公允价值变动成为净利润暴跌的主因，公司此前通过投资布局积累的"CRO+投 资"模式，因市场波动导致资产价值缩水，直接影响当期利润，凸显了该模式的收益与风险并存特征。 利润方面，公司去年归母净利润4.05亿元，同比下滑79.99%，主要受非经常性损益项目（如金融资产公允价值变 动）拖累；扣非净利润8.55亿元，同比下降42.13%。 《华夏时报》记者梳理资料发现，泰格医药在2020年至2024年期间，购买了不少的上市公司股票，这部分股票组 成的其他非流动金融资产，便是公司公允价值变动导致净利润大幅下滑的主要原因。 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 以公允价值计量且其变动计入当期损 | 1 ...

Group 1 - The Hong Kong pharmaceutical outsourcing sector experienced a significant decline, with major companies reporting substantial drops in stock prices [1] - Kanglong Chemical (03759.HK) saw a decrease of 13.27%, while Tigermed (03347.HK) fell by 11.33% [1] - Other notable declines included WuXi Biologics (02269.HK) down 8.19%, Kelaiying (06821.HK) down 7.52%, and WuXi AppTec (02359.HK) down 5.64% [1]

Core Viewpoint - WuXi AppTec (603259.SH, 02359.HK) announced a block trade to reduce its stake in WuXi Biologics (02268.HK) by 50.8 million shares, accounting for approximately 4.23% of WuXi Biologics' total share capital, with a transaction value of about HKD 2.178 billion [1][3]. Group 1: Share Reduction and Financial Impact - This marks the third reduction by WuXi AppTec since November 2024, with a cumulative reduction amounting to HKD 4.6 billion [3]. - The recent share reduction occurred when WuXi Biologics' stock price reached an all-time high [3]. - The investment gain from this reduction is approximately RMB 1.847 billion, representing over 10% of the projected net profit for 2024 [5]. Group 2: Strategic Response to Market Conditions - The global pharmaceutical outsourcing industry is facing intensified competition, with WuXi AppTec encountering multiple challenges from geopolitical and trade policies [5]. - Approximately 64% of WuXi AppTec's revenue is derived from the U.S. market, making it vulnerable to the impending "reciprocal tariff" policy, which could significantly impact its profitability [5]. - In response, WuXi AppTec is accelerating its global expansion, including the construction of a new facility in Middleton, USA, expected to be operational by the end of 2026 [5][6]. Group 3: Future Growth and Talent Acquisition - The funds raised from the share reduction will be primarily allocated to accelerate global capacity building, attract and retain top talent, and enhance its integrated CRDMO business model [5][6]. - WuXi Biologics, as the second-largest ADC CRDMO company globally, reported impressive performance in 2024, with revenues of RMB 4.052 billion, a year-on-year increase of 90.8%, and a net profit growth of 277.2% [6]. - The independent operation of WuXi Biologics allows it to focus on high-value areas such as ADC research and production, while WuXi AppTec can concentrate more resources on its core business, strengthening its leading position in the global pharmaceutical outsourcing market [6][7].

Core Viewpoint - WuXi AppTec is actively advancing the construction of its Middleton facility in the U.S., with plans to commence operations by the end of 2026. The company has also announced a third round of share reduction in WuXi AppTec's subsidiary, WuXi Biologics, since November of the previous year, indicating a strategic move to enhance its global capacity and talent retention [1][3]. Group 1: Share Reduction Details - On April 1, WuXi AppTec sold 50.8 million shares of WuXi Biologics, accounting for approximately 4.23% of the total share capital, with a transaction value of about HKD 2.178 billion, representing 3.43% of the company's latest audited net assets attributable to shareholders [1][3]. - The share reduction coincided with WuXi Biologics reaching a record high stock price of HKD 49.50 per share on the same day [1]. Group 2: Financial Implications - The proceeds from the share reduction will contribute an estimated investment income of CNY 1.847 billion to WuXi AppTec's 2025 semi-annual report [3]. - In 2024, revenue from U.S. clients is projected to be CNY 25.02 billion, making up approximately 64% of the company's total revenue, highlighting the significance of the U.S. market to WuXi AppTec's financial performance [3]. Group 3: Geopolitical Considerations - The company is facing uncertainties due to the impending implementation of U.S. "reciprocal tariffs," which could impact its revenue, particularly since the U.S. is its largest market [3]. - Management has acknowledged the global nature of tariff impacts and indicated that the specific effects on the company's business remain unclear and will require further observation [3].

Core Viewpoint - WuXi AppTec's stock price surged following the announcement of its revenue growth forecast for 2024, driven by the expansion of the obesity drug market and the implications of U.S. tariff policies [2][4]. Group 1: Revenue Growth and Business Expansion - WuXi AppTec expects its overall revenue to reach between 41.5 billion to 43 billion yuan in 2024, surpassing the revenue peak driven by COVID-19 commercialization in 2023 [2]. - The TIDES (oligonucleotide and peptide) business has become a new revenue growth engine, with projected revenue of 5.8 billion yuan in 2024, representing a year-on-year increase of 70.1% [2]. - By the end of 2024, TIDES' order backlog is expected to grow by 103.9% year-on-year [2]. Group 2: Market Demand and Production Capacity - The TIDES business is involved in the contract manufacturing of GLP-1 drugs, which have seen significant success in the obesity treatment sector, attracting investments from major pharmaceutical companies [3]. - WuXi AppTec holds over 20 GLP-1 projects, capturing more than 20% of the market share, indicating strong future demand for production capacity [3]. - The company is expanding its production capacity, with the total volume of peptide solid-phase synthesis reactors expected to increase to 41,000 liters by the end of 2024 and over 100,000 liters by the end of 2025 [2]. Group 3: U.S. Market and Policy Implications - The U.S. market is the largest revenue source for WuXi AppTec, contributing 25.02 billion yuan, which accounts for approximately 64% of the company's total revenue [4]. - The management acknowledged the uncertainty surrounding U.S. tariff policies and stated that the specific impact on the company's business remains unclear and will require further observation [4]. - Regarding the U.S. Biologics Act, the management noted that there have been no recent proposals related to this legislation and that the company will continue to monitor legislative developments closely [4].

其实昨天中国选手里，真正掉大分的是覃海洋的100米蛙泳决赛。这位25岁的新晋蛙王去年世锦赛拿了50米、100米、200米三个冠军，被寄予了厚望。这 次决赛的前50米排名第一，但后50米游崩了，竟然掉到了第7，看的人莫名其妙。 …… 今天的a股.......乏善可陈，成交量连6000亿都没有了，中位数小跌0.12%，北上的外资又抛了50亿，单单计算2024年的话，外资对a股已经快变成净流出 了。 我听到个小道消息，8月中旬后北上数据会进一步限制发布，可能是觉得这个比较负面，不希望外资的持续流出打击大家对a股的信心。这不禁让我又想起 费翔老师的著名台词，啊啊啊啊啊啊，嗯嗯嗯嗯嗯。 现在的a股真是一筹莫展，昨晚有读者问我如果去当证监会主席，有什么措施救市。我老实说救不了一点，我能想到的点子其实监管层都已经落实了，现 在最大的问题是市场信心进入了负面螺旋，这是行政力量无法逆转的。之前最大的利好印花税都减半了，结果也是高开低走吃了个大阴棒，你们说还能如 何呢... 现在只能耐心等市场自身构筑一个信心的底部，也许三五个月，也许好几年，这种玄而又玄的东西谁也没有时间表。我是经历过两次熊市的，所以心态还 算平和，但陆陆续续有 ...